MORPHOSYS AG O.N.
Commented by André Will-Laudien on May 2nd, 2022 | 13:27 CEST
BioNTech, Defence Therapeutics, Valneva, MorphoSys - Biotech stocks that will still be fun tomorrow!
One of the most churned areas on the growth stock market is the biotech sector. There was too much disappointment on the drug development side; even in the COVID sector, only a few winners remain. However, the current sell-off could turn out to be an entry opportunity in the medium term because there are more and more people on earth and, fortunately, they are getting older and older; even the Corona pandemic is not likely to change this. There are already 1 billion people worldwide over the age of 60, and forecasts predict that this figure will rise to 2 billion by 2050 - with a total population of more than 9 billion people predicted at that time. Which values have been unjustly neglected, and where are the current opportunities for investors?Read
Commented by André Will-Laudien on March 30th, 2022 | 11:36 CEST
The intensity of fluctuation on the capital markets remains high. It is measured by volatility indices such as the EU Vola Index or the VIX on the S&P 500. Both indices had risen well above 30 at the beginning of the crisis, with the EU Vola Index even reaching a peak of 43.3% on March 7. At the beginning of the Corona Lockdown in February 2020, this index rose overnight to values of over 70%. Although these volatility coefficients are slowly trending downwards due to political easing tendencies, hedgers on the derivatives markets are pricing volatility into their products at a higher price. So those who are currently trading options may experience their blue miracle with Vola changes overnight. Some stocks have recently jumped in this environment; where are the opportunities?Read
Commented by André Will-Laudien on March 21st, 2022 | 13:10 CET
The biotech sector, especially around vaccine manufacturers, has recently fallen somewhat out of fashion - Germany's most extensive Corona measures have likely already taken place. The general willingness to vaccinate can hardly be increased, and the vaccination obligation was dropped without a trace after lawyers formed a massive wave of lawsuits. But now that the Omicron infection figures are exploding to unimagined heights, we can expect a hot autumn again after a summer with a breather. "Corona has come to stay!" said Karl Lauterbach when he was not yet health minister. We take a look at some shares that have recently rebounded strongly.Read
Commented by Carsten Mainitz on March 14th, 2022 | 12:47 CET
Developing a blockbuster drug is the highest achievement in the pharmaceutical industry. A blockbuster is defined as a drug that can generate more than USD 1 billion in revenues per year. According to experts, the vaccine Comirnaty, developed by BioNTech and Pfizer, is likely to have brought in sales of well over USD 30 billion, thus clearly breaking the blockbuster barrier. Outside of vaccine research, there are also numerous companies with high long-term potential.Read
Commented by Armin Schulz on March 7th, 2022 | 13:05 CET
Every pharmaceutical or biotech company wants a blockbuster. This term refers to a drug that generates annual sales of at least USD 1 billion. The best-known blockbuster drug currently is the Corona vaccine from BioNTech. In 2020, the rheumatism drug Humira was in the top spot with sales of over USD 20 billion. The Mainz-based vaccine manufacturer is likely to have significantly surpassed this mark in 2021. If a company hits the big time, it can reap the rewards for 20 years before the patent expires. Today, we take a look at three companies that have potential blockbusters.Read
Commented by André Will-Laudien on February 15th, 2022 | 12:30 CET
Attention: Siemens Healthineers, Perimeter Medical Imaging AI, MorphoSys, Siemens - Riding the next hype with MedTech!
MedTech and pharma giants have been in high demand not only since the pandemic. The technification of diagnostics leads to the early detection of serious diseases and shortens the planning of necessary medical interventions. Of course, COVID-19 significantly impacts the availability and additional demand for high-tech in practices and emergency departments. It is creating a boom in demand from manufacturers rarely seen at this headline rate. We are looking at clear winners in medical digitization.Read
Commented by André Will-Laudien on February 9th, 2022 | 12:22 CET
The biotech sector is a highly dynamic growth market within the equity universe. It is characterized by investment volumes of unprecedented size, which is also the reason for the high innovation rate characteristic of the sector. Price reactions to positive or negative surprises can be very volatile, and these tendencies are often exacerbated by the intervention of stop orders or the occurrence of derivative slippage. Vaccine manufacturers were down over 50% across the board, as the pandemic is being traded as a phase-out. The vaccination rate does not appear to be increasing significantly. Where are the opportunities for investors at the moment?Read
Commented by Carsten Mainitz on February 4th, 2022 | 12:22 CET
The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.Read
Commented by Carsten Mainitz on January 26th, 2022 | 13:34 CET
The Corona pandemic still has the world firmly in its grip. The number of new infections is skyrocketing. Nevertheless, the chances are good that the pandemic can be brought under control by means of numerous vaccines. But Corona is not the only scourge. Numerous research efforts are focused on diagnosing, treating and curing cancer. Here, innovative AI-based technologies are increasingly being used to help save lives and significantly reduce costs for the healthcare system.Read
Commented by Armin Schulz on January 12th, 2022 | 13:42 CET
Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.Read